Companies vent rejection dismay

Posted 22 August 2022 AM

Companies were vocal in their disappointment after the PBAC rejected a long line of change to listing requests at its July meeting, with cost the stumbling block in almost every case.

Chiesi's Epidyolex for the treatment of Lennox-Gastaut Syndrome in patients aged two years and older was not recommended for the fourth time.

To see the whole article, please login

Popular

HCPs vote for best pharma

Disruption coming to Med Affairs

$56M drug hit with first generic

Not just an office, it's a destination

Latest Jobs

Procurement Specialist - Indirect

Customer Service Representative

Specialist Account Manager

Hospital Specialist Representative

Vice President - Research & Development

See all...

Pharma in Focus Jobs

Marketing & Communications (3)

Sales & Customer Relations (16)

Clinical & Medical, R&D (7)

Other (6)

MORE NEWS

Email this article to a friend

From:

Subject

Friend's email

Message to go with the article

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.

Skip password for now